Carol Fabian, MD

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Carol Fabian, MD sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials 1 currently recruiting 11 completed early-phase tilt top decile by trial count

Carol Fabian, MD: 14 sponsored US clinical trials, 1 recruiting.

Carol Fabian, MD sponsors 14 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 2 trials.

Top-decile sponsor footprint

Carol Fabian, MD ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

11 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

14 total, page 1 of 1

RECRUITING

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

NCT00291096
COMPLETED Early Phase 1

Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers

NCT04821375
TERMINATED Early Phase 1

Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms

NCT04379024
COMPLETED NA

High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women

NCT03270111
COMPLETED Early Phase 1

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

NCT02517502
COMPLETED NA

Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women

NCT02101970
TERMINATED Phase 2

Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

NCT01276704
COMPLETED Phase 2

Breast Cancer Risk Biomarkers in Premenopausal Women

NCT01252277
COMPLETED Phase 2

Breast Cancer Risk Biomarkers in Postmenopausal Women

NCT01252290
COMPLETED NA

Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D

NCT01166763
COMPLETED Phase 2

Study of Breast Cancer Prevention by Letrozole in High Risk Women

NCT00579826
COMPLETED

Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer

NCT00291083
COMPLETED Phase 2

Protocol for Women at Increased Risk of Developing Breast Cancer

NCT00291694
COMPLETED Phase 2

Protocol for Women at Increased Risk of Developing Breast Cancer

NCT00291135

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 6

Therapeutic Areas

Breast Cancer 2
Cognitive Dysfunction 1

What is open in the Carol Fabian, MD pipeline

1 recruiting of 14 indexed (7% open); 11 completed (79%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (2 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Carol Fabian, MD: open-pipeline peers nationwide

Peers matched on 14 registered trials and 7% open enrollment, not the therapeutic-area sidebar.

Carol Fabian, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%2%4%6%8% Total trials Recruiting share Carol Fabian, MD3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USACelldex TherapeuticsKaiser PermanenteMannkind CorporationMinneapolis Veterans Affairs Medical Center
Carol Fabian, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Carol Fabian, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 trials (± recruiting share)

Sponsors near 7% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Carol Fabian, MD page

14 registered trials is a research-attention snapshot, not an endorsement of Carol Fabian, MD or any single study.

  • 1 of Carol Fabian, MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Carol Fabian, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Carol Fabian, MD pipeline card: 14 registered trials from official public datasets.Report a data error.